22 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
the 1st adult patient was dosed with this compound)
Planet Care
Q1 2024
Q4 2023
Climate change - Carbon footprint
(CO2 emissions)
55% reduction
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
on climate change and health, going beyond its own operations and Foundation S stressed the importance of channeling philanthropic funds to help … vulnerable populations adapt to climate change.
As a company committed to fight climate change and its impact on health, Sanofi has taken the lead
6-K
EX-99.5
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
philanthropic organization.
Dr Ibrahima Socé Fall
Director of Neglected Tropical Diseases, World Health Organization
“The impact of climate change extends … , and hepatitis C. Its research priorities include children’s health, gender equity and gender-responsive R&D, and diseases impacted by climate change. Since
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
preparation for clinical study
2 external collaboration
contracts with the pediatric ITCC consortium established
Planet Care
Climate change - Carbon
6-K
EX-99.1
SNY
Sanofi
27 Sep 23
Current report (foreign)
6:06am
Exhibit 99.1
Press Release
Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
Paris … to positively impact society by tackling climate change and its consequences for human health.
Ramping up adaptation efforts and initiatives to address
6-K
xt8nmrx5b4q1jed4l2p
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.2
8tsgkf9vekmim8sal
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
pdaxv4cc38696iu7
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
y6jvsec7ogjwj6 qr6c
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
7bqyl
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
queulgr 2v56
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
ovyl5za52
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
mvqxha18 elf8su295
8 Jul 22
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
11:01am
6-K
EX-99.2
32h97mj72oo
9 May 22
Approval of the financial statements for the fiscal year 2021
2:29pm
6-K
EX-99.1
47258t6
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
b86xgub 5oh77co
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
6-K
EX-99.3
i9ey 56fo4nk
8 Jun 21
Sanofi launches its new global employee share ownership plan
1:31pm
6-K
EX-99.4
ls68d5kn5a2 57r18
13 Apr 21
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
2:56pm
6-K
EX-99.2
2ock1 kner49
11 Dec 20
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
3:25pm